Northeast Health Wangaratta is participating in a clinical trial investigating treatments that manage blood pressure to improve outcomes of patients with septic shock.
The ARISE FLUIDS Clinical Trial is being conducted in hospitals across Australia and New Zealand, involving patients who present to the Emergency Department with septic shock. Participants will receive one of two commonly used treatments to manage blood pressure. Participants will be followed up by the NHW Clinical Trial team for a period of 12 months to assess clinical outcomes.
NHW joined the ARISE FLUIDS Clinical Trial before Christmas 2023, and it took less than 24 hours to enrol their first participant. Since then, a further two participants have been enrolled.
NHW Director of Intensive Care, Prof David Tuxen said it is an important Clinical Trial, and NHW is keen to be a significant contributor.
“The trial is well underway and we’re anticipating that at least one patient per month will meet the criteria for the trial,” Prof Tuxen said.
“We often treat patients with septic shock arising from other conditions such as urinary infections or pneumonia and these are the types of presentations that we would include.”
“Treatment will be randomised so that patients receive either restricted fluids and early introduction of vasopressors to manage their blood pressure, or a larger initial volume of IV fluid.”
“The goal is to provide robust evidence around the best approach to use in the future management of septic shock.”
A total of 1000 participants are being included in the study across Australia and New Zealand, with the results expected to be available after 2025. At present, a total of 465 participants have been enrolled across 40 sites.